Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1026-1033

  Antoon, James W ^a   Bratton, Melyssa R ^a   Guillot, Lori M ^a   Wadsworth, Scott ^b   Salvo, Virgilio A ^a   Burow, Matthew E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ETHICON INC   (United States)

Author keywords

Breast cancer; Drug discovery; Estrogen receptor; Mitogen activated protein kinase; p38; SRC

Indexed keywords

4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN KINASE P60; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HEK293 CELLS; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 84865853835     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20992     Document Type: Article

References (44)

1. Geh E, Meng Q, Mongan M, Wang J, Takatori A, Zheng Y, et al. Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) integrates developmental signals for eyelid closure. Proc Natl Acad Sci USA 2011; 108:17349-54; PMID:21969564; http://dx.doi.org/10.1073/pnas.1102297108.
2. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Update 2001; 4:253-67. (Pubitemid 34456379)
3. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, et al. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 2002; 80:239-56; PMID:11897507; http://dx.doi.org/10.1016/ S0960-0760(01)00189-3.
4. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4:937-47; PMID:15573115; http://dx.doi.org/10.1038/nrc1503.
5. Tenhunen O, Sármán B, Kerkelä R, Szokodi I, Papp L, Tóth M, et al. Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J Biol Chem 2004; 279:24852-60; PMID:15051723; http://dx.doi.org/10.1074/jbc.M314317200.
6. Maemura M, Iino Y, Koibuchi Y, Yokoe T, Morishita Y. Mitogen-activated protein kinase cascade in breast cancer. Oncology 1999; 57:37-44; PMID:10545801; http://dx.doi.org/10.1159/000055273.
7. Massarweh S, Schiff R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin Cancer Res 2007; 13:1950-4; PMID:17404074; http://dx.doi.org/10.1158/1078-0432.CCR-06-2540.
8. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, et al.; NCI-Naple Breast Cancer Group. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12:721-47; PMID:16322319; http://dx.doi.org/10.1677/erc.1.00857.
9. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009; 9:631-43; PMID:19701242; http://dx.doi.org/10.1038/nrc2713.
10. Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle 2006; 5:824-8; PMID:16627995; http://dx.doi.org/10.4161/cc.5.8.2685.
11. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010; 429:403-17; PMID:20626350; http://dx.doi.org/10.1042/BJ20100323.
12. Lee H, Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Mol Cell Biol 2002; 22:5835-45; PMID:12138194; http://dx.doi.org/10.1128/MCB.22.16.5835-45.2002.
13. Frigo DE, Basu A, Nierth-Simpson EN, Weldon CB, Dugan CM, Elliott S, et al. p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1. Mol Endocrinol 2006; 20:971-83; PMID:16410316; http://dx.doi.org/10.1210/me.2004- 0075.
14. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270:1491-4; PMID:7491495; http://dx.doi.org/10. 1126/science.270.5241.1491.
15. Baan B, van der Zon GC, Maassen JA, Ouwens DM. The nuclear appearance of ERK1/2 and p38 determines the sequential induction of ATF2-Thr71 and ATF2-Thr69 phosphorylation by serum in JNK-deficient cells. Mol Cell Endocrinol 2009; 311:94-100; PMID:19647037; http://dx.doi.org/10.1016/j.mce.2009.07.023.
16. Suen CS, Berrodin TJ, Mastroeni R, Cheskis BJ, Lyttle CR, Frail DE. A transcriptional coactivator, steroid receptor coactivator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 1998; 273:27645-53; PMID:9765300; http://dx.doi.org/10.1074/jbc.273.42.27645.
17. Proia DA, Nannenga BW, Donehower LA, Weigel NL. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem 2006; 281:7089-101; PMID:16352595; http://dx.doi.org/10.1074/jbc.M511839200.
18. Chai Z, Yang L, Yu B, He Q, Li WI, Zhou R, et al. p38 mitogen-activated protein kinase-dependent regulation of SRC-3 and involvement in retinoic acid receptor alpha signaling in embryonic cortical neurons. IUBMB Life 2009; 61:670-8; PMID:19472184; http://dx.doi.org/10.1002/iub.212.
19. Oñate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995; 270:1354-7; PMID:7481822; http://dx.doi.org/10.1126/science.270. 5240.1354.
20. McInerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc Natl Acad Sci USA 1996; 93:10069-73; PMID:8816752; http://dx.doi.org/10.1073/pnas.93.19.10069.
21. Norris JD, Fan D, Stallcup MR, McDonnell DP. Enhancement of estrogen receptor transcriptional activity by the coactivator GRIP-1 highlights the role of activation function 2 in determining estrogen receptor pharmacology. J Biol Chem 1998; 273:6679-88; PMID:9506965; http://dx.doi.org/10.1074/jbc.273.12.6679.
22. Rane MJ, Coxon PY, Powell DW, Webster R, Klein JB, Pierce W, et al. p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phos-phoinositide-dependent kinase-2 for Akt in human neutrophils. J Biol Chem 2001; 276:3517-23; PMID:11042204; http://dx.doi.org/10.1074/jbc.M005953200.
23. Kato K, Ito H, Kamei K, Iwamoto I. Selective stimulation of Hsp27 and alphaB-crystallin but not Hsp70 expression by p38 MAP kinase activation. Cell Stress Chaperones 1999; 4:94-101; PMID:10547059.
24. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006; 25:2987-98; PMID:16407830; http://dx.doi.org/10.1038/sj.onc.1209337.
25. Sudo T, Kawai K, Matsuzaki H, Osada H. p38 mitogen-activated protein kinase plays a key role in regulating MAPKAPK2 expression. Biochem Biophys Res Commun 2005; 337:415-21; PMID:16198317; http://dx.doi.org/10.1016/j.bbrc.2005. 09.063.
26. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2 and p38 mitogen-activated protein kinase. J Clin Oncol 2005; 23:2469-76. (Pubitemid 47050837)
27. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990; 9:2811-8; PMID:2118104.
28. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 1994; 8:21-30; PMID:8152428; http://dx.doi.org/10.1210/me.8.1.21.
29. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999; 140:5566-78; PMID:10579320; http://dx.doi.org/10.1210/en. 140.12.5566.
30. Zhang QX, Borg A, Wolf DM, Oesterreich S, Fuqua SA. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997; 57:1244-9; PMID:9102207.
31. Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, et al. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol 2011; 46:205-16; PMID:21321095; http://dx.doi.org/10.1530/JME-10-0116.
32. Antoon JW, White MD, Slaughter EM, Driver JL, Khalili HS, Elliott S, et al. Targeting NFκB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011; 11:678-89; PMID:21307639; http://dx.doi.org/10.4161/cbt.11.7.14903.
33. Soule HD, Maloney TM, Wolman SR, Peterson WD Jr, Brenz R, McGrath CM, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50:6075-86; PMID:1975513.
34. Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G. p38gamma mitogen-activated protein kinase integrates signaling crosstalk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res 2006; 66:7540-7; PMID:16885352; http://dx.doi.org/10.1158/0008-5472.CAN-05-4639.
35. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007; 1773:1358-75.
36. Muthumani K, Wadsworth SA, Dayes NS, Hwang DS, Choo AY, Abeysinghe HR, et al. Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor. AIDS 2004; 18:739-48; PMID:15075508; http://dx.doi.org/10.1097/00002030-200403260-00004.
37. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12:1-13; PMID:10676842; http://dx.doi.org/10.1016/ S0898-6568(99)00071-6.
38. Antoon JW, Liu J, Ponnapakkam AP, Gestaut MM, Foroozesh M, Beckman BS. Novel D: -erythro N-octanoyl sphingosine analogs as chemo- and endocrine-resistant breast cancer therapeutics. Cancer Chemother Pharmacol 2010; 65:1191-5; PMID:20155475; http://dx.doi.org/10.1007/s00280-009-1233-0.
39. Antoon JW, Liu J, Gestaut MM, Burow ME, Beckman BS, Foroozesh M. Design, synthesis and biological activity of a family of novel ceramide analogues in chemoresistant breast cancer cells. J Med Chem 2009; 52:5748-52; PMID:19694470; http://dx.doi.org/10.1021/jm9009668.
40. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, et al. Differences in susceptibility to tumor necrosis factoralpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 1998; 58:4940-6; PMID:9810003.
41. Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, et al. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 2010; 151:5124-35; PMID:20861237; http://dx.doi.org/10.1210/en. 2010-0420.
42. Bratton MR, Frigo DE, Vigh-Conrad KA, Fan D, Wadsworth S, McLachlan JA, et al. Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase. Carcinogenesis 2009; 30:106-13; PMID:18791200; http://dx.doi.org/10.1093/carcin/bgn213.
43. Antoon JW, Beckman BS. Anti-proliferative effects of the novel ceramide analog (S)-2-(benzylideneamino)-3-hydroxy-N-tetrade-cylpropanamide in chemoresistant cancer. Bioorg Med Chem Lett 2012; 22:2624-8; PMID:22366655; http://dx.doi.org/10.1016/j.bmcl.2012.01.087.
44. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, et al. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004; 309:523-32; PMID:14742741; http://dx.doi.org/10.1124/jpet.103.062760.